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tients who began treatment with either olanzapine or ris-
peridone were included. Treatment course and associated
schizophrenia-related, mental health care and total health
care costs during the subsequent 12-month period were
examined using univariate and multivariate methods.
RESULTS: Nine hundred eighty-five (985) patients initi-
ated on risperidone and 348 initiated on olanzapine met
inclusion criteria. The mean dose was 4.02 and 10.49 for
risperidone and olanzapine patients, respectively. Patients
taking olanzapine versus risperidone stayed on therapy
longer during the 12-month observation period (217 days
versus 181 days, p  0.0001). Although pharmaceutical
costs were significantly higher for olanzapine patients,
their medical costs were significantly lower than those on
risperidone. After adjusting for differences in patient de-
mographics, disease severity and comorbidities, olanza-
pine patients had significantly lower mental health care
costs including drug costs ($1,827 less, p  0.05) and
lower total health care costs ($1,834 less, p  0.05). The
schizophrenia-related costs (including drug costs) were
not statistically significantly different, though numeri-
cally the risperidone patients incurred $740 more per pa-
tient than patients on olanzapine (p  0.26). CONCLU-
SIONS: The findings in this study suggest that the initial
selection of atypical antipsychotic for the treatment of
schizophrenia matters, as olanzapine offset its acquisition
cost by reducing medical costs and demonstrated signifi-
cant mental and total health care cost savings over ris-
peridone.
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OBJECTIVES: The Positive And Negative Syndrome
Scale (PANSS) and Calgary Depression Scale for Schizo-
phrenics (CDSS) are widely used in the evaluation of
schizophrenia. Their internal validity have already been
evaluated with classical methods (multitrait and confir-
matory analyses). During the last two decades, Item Re-
sponse Theory has been developed to deal with latent
traits. As part of it, Rasch models are commonly used in
Quality of Life research but not yet for other outcome
questionnaires. METHODS: 458 schizophrenic patients
were evaluated with the PANSS and CDSS. Rasch models
for polytomous items were fitted to the data in order to
assess: 1) unidimensionality of the CDSS and the PANSS
subscales, i.e. their ability to measure one latent trait (de-
gree of depression/degree of positive, negative, general
schizophrenic symptoms); infit and outfit statistics were
used and residuals studied; 2) invariance of comparisons,
implying that the parameter characterizing an item does
not depend on the latent trait distribution of the popula-
tion; item parameters estimates were compared for two
subgroups of the population. RESULTS: Unidimension-
ality and invariance of comparisons are globally satisfac-
tory for the CDSS, although the appropriateness of two
items (items four and seven) may be questionable. Results
do not support the three-dimensional structure for the
PANSS, which is commonly used as the reference. CON-
CLUSIONS: Further investigation of the factorial struc-
ture of PANSS (e.g five-factors structures, which have
been proposed by several authors) is necessary. Rasch
models provide a powerful approach to evaluate internal
validity of mental health scales, enabling to investigate
invariance of comparisons, which constitutes the major
distinction from classical methods.
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OBJECTIVES: Health economic assessment of cost-effec-
tiveness parameters for the comparison of typical (Halo-
peridol), partially atypical depot (Flupentixol) and atypi-
cal neuroleptics (Olanzapin, Risperidon) in the treatment
of schizophrenia from the perspective of German health
insurance. METHODS: A published markov model was
rebuilt and calibrated with DATA®, taking into consid-
eration relapse rates, extrapyramidal symptoms (EPS)
and other prognostic symptoms. All data were derived
from published sources where available. Besides the com-
parison of monotherapy, a stepwise treatment scenario
was simulated, starting with three months Olanzapin
treatment followed by Flupentixol. Over the 5-year simu-
lation period cumulated complication rates (percentage
of relapse, positive and negative symptoms), patient re-
lated outcomes (Brief Psychiatric Rating Score “BPRS”)
and cost parameters (medication, EPS-cost and total
costs) were assessed. A cost-effectiveness analysis was
performed. RESULTS: Olanzapin/Flupentixol in combi-
nation had the lowest relapse rate (42.9 %), followed by
Flupentixol (44.4%), Olanzapin (44.8%), Risperidon
(48.0 %) and Haloperidol (57.6%). Olanzapin treatment
showed the highest BPRS score (3.13), followed by Ris-
peridon (3.07), Olanzapin/Flupentixol (2.52), Flupen-
tixol (2.42) and Haloperidol (2.37). The most cost-effec-
tive treatment measured by cost in DEM per relapse free
patient was Olanzapin/Flupentixol (200,000), followed
by Olanzapin (211,000), Flupentixol (212,000), Risperi-
don (231,000) and Haloperidol (287,000). The best cost-
effectiveness (expressed in DEM/BPRS) was observed in
Olanzapin (37,100), followed by Risperidon (39,100),
Olanzapin/Flupentixol (45,500), Flupentixol (48,600)
and Haloperidol (51,400). Total 5-year drug cost (DEM)
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were 24,600, 26,800, 3,800, 2,700 and 3,210 respec-
tively. CONCLUSIONS: In terms of relapse rates Olan-
zapin and Flupentixol lead to better clinical outcome and
better cost-effectiveness results as compared to alterna-
tive typical or atypical neuroleptic therapy. With Olanza-
pin and Risperidon most favorable BPRS scores were
achieved. Flupentixol depot as monotherapy or following
initial Olanzapin treatment is a cost-effective alternative
to atypical neuroleptics at low drug cost and low relapse
rates.
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OBJECTIVES: Approximately one-half of patients with
an episode of major depression will have a recurrent epi-
sode during their lifetime. Recent studies indicate that ap-
proximately 20% of depressed patients are resistant to
traditional antidepressant treatments. This study utilizes
medical and prescription claims data from the 1995–
1998 MarketScan® Databases to profile the characteris-
tics and health care utilization of patients with treatment-
resistant depression. METHODS: Depression-diagnosed
patients with adequate antidepressant dosing and treat-
ment duration are selected. Patients are classified as treat-
ment-resistant if they have switched/augmented their ini-
tial medication with other antidepressants twice, or if
they have switched/augmented their initial medication
and have claims for depression-related hospitalizations or
suicide attempts. Depression-diagnosed patients meeting
selection criteria but not classified as treatment-resistant
by the above criteria are used as a comparison group.
RESULTS: Patients with treatment-resistant depression
are at least twice as likely to be diagnosed with bipolar
disorder, at least 1.5 times as likely to be diagnosed with
comorbid anxiety disorders, and at least 1.5 times as
likely to be diagnosed with substance-related disorders
than the comparison group (p-values 0.01). Patients
with treatment-resistant depression have 30% higher
mean number of psychiatric diagnostic groupings (PDG)
and 9% higher mean number of major diagnostic catego-
ries (MDC) than the comparison group (p-values 0.01).
Furthermore, patients with treatment-resistant depres-
sion are at least twice as likely to be hospitalized (depres-
sion and non-depression related), and have 41% more
outpatient visits than the comparison group (p-values
0.01). Finally, patients with treatment-resistant depres-
sion use 2 to 3 times more psychotropic medications (in
addition to antidepressants) than the comparison group
(p-values 0.01). CONCLUSIONS: Treatment-resistant
patients are higher utilizers of both depression-related
and general medical services. This finding underscores
the importance of early identification and effective treat-
ment of treatment-resistant patients to prevent future de-
pressive episodes and to mitigate health care utilization.
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OBJECTIVES: Health care utilization for patients with
bipolar disorder has received limited attention. This
study utilizes medical and prescription claims data from
the 1998 to mid-2000 MarketScan Databases to examine
the risks of hospitalization, a major cost driver in treating
bipolar patients. Hospitalizations are associated with a
relapse of bipolar symptoms (often due to treatment inef-
fectiveness or discontinuation). METHODS: Bipolar pa-
tients are identified using diagnosis codes and prescrip-
tion drug claims. An ‘intent-to-treat’ framework for
classifying drug cohorts by initial bipolar prescription is
used. Prescription claims are studied over a minimum of
a six-month time period to analyze drug use patterns
(e.g., switching and augmenting treatment). Descriptive
profiles of the bipolar patients are presented. Cox pro-
portional hazard models are used to examine the rela-
tionships among observable patient characteristics, drug
choice, drug use patterns, and hospitalizations. This
method accounts for the potential bias in parameter esti-
mates due to data censoring. RESULTS: Among patients
with at least 6-months of follow-up data (n  6,536), the
mean age is 43 years old and 63.3% are female. The
majority of patients are initially observed on antimanic
medications, with lesser percentages on other common
pharmacological therapies (typical and atypical antipsy-
chotics, and antiepileptics). During the 6-month follow-
up, 14.5% of patients have at least one hospitalization
and 7.2% have at least one bipolar-related hospitaliza-
tion. During a 12-month follow-up, 23.3% have at least
one hospitalization of any type and 11.5% have at least
one bipolar-related hospitalization. The unadjusted risk
of hospitalization increases over time, at a decreasing
rate. CONCLUSION: The high incidence of hospitaliza-
tion demonstrates the need for effective treatment op-
tions. This study also illustrates the importance of ac-
counting for censored data to obtain unbiased estimates
of factors associated with the risk of hospitalization.
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OBJECTIVES: Use of benzodiazepines in elderly patients
has been associated with adverse outcomes including mo-
